related to history · 34Imatinib → After, Anthony, Biological Studies, Brian Druker, British, California, Carlo Gambacorti-Passerini, Center, Charles Sawyers, Ciba-Geigy, CML, Elisabeth Buchdunger, Hammersmith Hospital, Hunter, Italy, John Goldman, Jürg Zimmermann, La Jolla, London, Memorial Sloan Kettering Cancer
related to Pharmacokinetics · 17Imatinib → Abelson, ABL, As, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FIP1L1-PDGFRalpha, It, Kit, Metabolism, Most, N-demethylated, P450, PDGFR, The
related to Other · 13Imatinib → ALL, CHIC2, D816V, FIP1L1-PDGFRα, For, Gleevec, January, KIT, On, Ph, Philadelphia, The FDA, There
related to Interactions · 12Imatinib → An, As, Conversely, CYP2C9, CYP2D6, CYP3A4, Inactivated, Its, Likewise, Since, St John's Wort, The
related to Economics · 11Imatinib → Blood, Brian Druker, Carlo Gambacorti-Passerini, Druker, In, John Goldman, Novartis, Other, Signatories, They, United States
related to Medical uses · 11Imatinib → ALL, ASM, CCyR, CML, DFSP, FDA, GISTs, In, It, MDS/MPD, MMR
related to Chronic myelogenous leukemia · 9Imatinib → By, CML, Drug Administration, Due, FDA, Food, Philadelphia, Starting, The
related to Cardiotoxicity · 7Imatinib → ABL, ABL1, Cardiotoxic, Clinical, In, Patient, Studies
related to Gastrointestinal stromal tumors · 7Imatinib → February, GIST, KIT-positive, KIT-positive GISTs, On, The, The FDA
related to Research · 7Imatinib → D816V, Experience, However, It, KIT, One, These
